Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-3232
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMeier, Noëmi R.-
dc.contributor.authorVolken, Thomas-
dc.contributor.authorGeiger, Marc-
dc.contributor.authorHeininger, Ulrich-
dc.contributor.authorTebruegge, Marc-
dc.contributor.authorRitz, Nicole-
dc.date.accessioned2019-06-05T12:28:25Z-
dc.date.available2019-06-05T12:28:25Z-
dc.date.issued2019-
dc.identifier.issn2296-2360de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/17228-
dc.description.abstractBackground: Interferon-gamma release assays (IGRA) are well-established immunodiagnostic tests for tuberculosis (TB) in adults. In children these tests are associated with higher rates of false-negative and indeterminate results. Age is presumed to be one factor influencing cytokine release and therefore test performance.The aim of this study was to systematically review factors associated with indeterminate IGRA results in pediatric patients. Methods: Systematic literature review guided by the preferred reporting items for systematic reviews and meta-analyses (PRISMA) searching PubMed, EMBASE, and Web of Science. Studies reporting results of at least one commercially available IGRA (QuantiFERON-TB, T-SPOT.TB) in pediatric patient groups were included. Random effects meta-analysis was used to assess proportions of indeterminate IGRA results. Heterogeneity was assessed using the I2 value. Risk differences were calculated for studies comparing QuantiFERON-TB and T-SPOT.TB in the same study.Meta-regression was used to further explore the influence of study level variables on heterogeneity. Results: Of 1,293 articles screened, 133 studies were included in the final analysis. These assessed QuantiFERON-TB only in 77.4% (103/133), QuantiFERON-TB and T-SPOT.TB in 15.8% (21/133), and T-SPOT.TB only in 6.8% (9/133) resulting in 155 datasets including 107,418 participants. Overall 4% of IGRA results were indeterminate, and T-SPOT.TB (0.03, 95% CI 0.02-0.05) and QuantiFERON-TB assays (0.05, 95% CI 0.04-0.06) showed similar proportions of indeterminate results; pooled risk difference was – 0.01 (95% CI 0.03-0.00). Significant differences with lower proportions of indeterminate assays with T-SPOT.TB compared to QuantiFERON-TB were only seen in subgroup analyses of studies performed in Africa and in non-HIV-infected immunocompromised patients. Meta-regression confirmed lower proportions of indeterminate results for T-SPOT.TB compared to QuantiFERON-TB only among studies that reported results from non-HIV-infected immunocompromised patients (p < 0.001). Conclusion: On average indeterminate IGRA results occur in 1 in 25 tests performed. Overall, there was no difference in the proportion of indeterminate results between both commercial assays. However, our findings suggest that in patients in Africa and/or patients with immunocompromising conditions other than HIV infection the T-SPOT.TB assay appears to produce fewer indeterminate results.de_CH
dc.language.isoende_CH
dc.publisherFrontiers Research Foundationde_CH
dc.relation.ispartofFrontiers in Pediatricsde_CH
dc.rightshttp://creativecommons.org/licenses/by/4.0/de_CH
dc.subjectClinical studyde_CH
dc.subjectIGRAde_CH
dc.subjectLatentde_CH
dc.subjectPediatricsde_CH
dc.subjectRisk differencede_CH
dc.subjectQuantiFERONde_CH
dc.subjectT-SPOT.TBde_CH
dc.subjectT cell responsede_CH
dc.subject.ddc616: Innere Medizin und Krankheitende_CH
dc.titleRisk factors for indeterminate interferon-gamma release assay for the diagnosis of tuberculosis in children : a systematic review and meta-analysisde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
zhaw.organisationalunitInstitut für Public Health (IPH)de_CH
dc.identifier.doi10.21256/zhaw-3232-
dc.identifier.doi10.3389/fped.2019.00208de_CH
zhaw.funding.euNode_CH
zhaw.issue208de_CH
zhaw.originated.zhawYesde_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume7de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
Appears in collections:Publikationen Gesundheit

Files in This Item:
File Description SizeFormat 
fped-07-00208.pdf8.02 MBAdobe PDFThumbnail
View/Open
Show simple item record
Meier, N. R., Volken, T., Geiger, M., Heininger, U., Tebruegge, M., & Ritz, N. (2019). Risk factors for indeterminate interferon-gamma release assay for the diagnosis of tuberculosis in children : a systematic review and meta-analysis. Frontiers in Pediatrics, 7(208). https://doi.org/10.21256/zhaw-3232
Meier, N.R. et al. (2019) ‘Risk factors for indeterminate interferon-gamma release assay for the diagnosis of tuberculosis in children : a systematic review and meta-analysis’, Frontiers in Pediatrics, 7(208). Available at: https://doi.org/10.21256/zhaw-3232.
N. R. Meier, T. Volken, M. Geiger, U. Heininger, M. Tebruegge, and N. Ritz, “Risk factors for indeterminate interferon-gamma release assay for the diagnosis of tuberculosis in children : a systematic review and meta-analysis,” Frontiers in Pediatrics, vol. 7, no. 208, 2019, doi: 10.21256/zhaw-3232.
MEIER, Noëmi R., Thomas VOLKEN, Marc GEIGER, Ulrich HEININGER, Marc TEBRUEGGE und Nicole RITZ, 2019. Risk factors for indeterminate interferon-gamma release assay for the diagnosis of tuberculosis in children : a systematic review and meta-analysis. Frontiers in Pediatrics. 2019. Bd. 7, Nr. 208. DOI 10.21256/zhaw-3232
Meier, Noëmi R., Thomas Volken, Marc Geiger, Ulrich Heininger, Marc Tebruegge, and Nicole Ritz. 2019. “Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children : A Systematic Review and Meta-Analysis.” Frontiers in Pediatrics 7 (208). https://doi.org/10.21256/zhaw-3232.
Meier, Noëmi R., et al. “Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children : A Systematic Review and Meta-Analysis.” Frontiers in Pediatrics, vol. 7, no. 208, 2019, https://doi.org/10.21256/zhaw-3232.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.